Sign in
Taking peopleNo phase

Vonaprazan Versus Esomeprazole for Healing of LA Grade B or Higher Esophagitis After POEM

Key facts

Who runs it
Asian Institute of Gastroenterology, India
Where
India1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
300 people, planned
Started
30 Apr 2025
Expected to end
25 Dec 2028
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Vonoprazan
  • Esomeprazole 40mg
Record updated
27 April 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (11)Hide the full registry criteria

Who can take part

  • Age ≥18 years
  • History of POEM for achalasia
  • Endoscopic confirmation of LA grade B, C, or D reflux esophagitis at 3 months post-POEM
  • GERD symptoms (heartburn, regurgitation) for ≥4 weeks
  • Willingness to provide informed consent and comply with study procedures

Who cannot take part

  • History of prior anti-reflux surgery
  • Regular use of NSAIDs, steroids, or anticoagulants affecting esophageal healing
  • Presence of Barrett's esophagus, esophageal stricture, or malignancy
  • Severe gastroparesis or esophageal motility disorder unrelated to achalasia
  • Severe hepatic or renal impairment (ALT/AST >3× ULN, eGFR <30 mL/min)
  • Pregnancy or breastfeeding

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Gerd

This trial is currently available in India.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Peroral Endoscopic Myotomy (POEM) is a well-established treatment for achalasia; however, it is frequently associated with gastroesophageal reflux disease (GERD), with many patients developing LA grade B or higher esophagitis. Proton pump inhibitors (PPIs) like Esomeprazole are the standard treatment, but Vonaprazan, a potassium-competitive acid blocker (P-CAB), offers superior acid suppression and may provide enhanced healing in post-POEM reflux esophagitis.

Read full original descriptionShow less

Primary Objective:

• To compare the healing rates of LA grade B or higher reflux esophagitis at 8 weeks in patients receiving Vonaprazan 20 mg versus Esomeprazole 40 mg.

Secondary Objectives

* To assess improvement in reflux symptoms using the GERD-Q score at 8 weeks. * To evaluate the incidence of adverse events in each treatment group.

The 2 groups in the trial

  • To assess the efficacy of vonapraprazon 20mg better than esomeprazole drugExisting treatment, for comparison

    healing rate will be checked during endoscopy at 8 weeks

    Treatment: Vonoprazan

  • To see the healing rate of grade B esophagitisPlacebo, for comparison

    healing rate will be checked during endoscopy at 8 weeks in patients receiving esomeprazole 40mg

    Treatment: Esomeprazole 40mg

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT06955520, who can take part
Record updated
27 April 2026